Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 267Neoplasms 177Colorectal Neoplasms 133Stomach Neoplasms 107Uterine Cervical Neoplasms 96Carcinoma, Non-Small-Cell Lung 89Prostatic Neoplasms 83Lung Neoplasms 78Carcinoma, Hepatocellular 73Rectal Neoplasms 64Ovarian Neoplasms 54Esophageal Neoplasms 53Pancreatic Neoplasms 52Colonic Neoplasms 52Recurrence 43Multiple Myeloma 39Neoplasm Metastasis 38Head and Neck Neoplasms 37Endometrial Neoplasms 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Motor Activity 34Melanoma 33Polycystic Ovary Syndrome 32Lymphoma 32Urinary Bladder Neoplasms 31Leukemia, Myeloid, Acute 30Thyroid Neoplasms 29Small Cell Lung Carcinoma 28Nasopharyngeal Carcinoma 25Lymphoma, Non-Hodgkin 25

Interventions

S 1 (combination) 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Advanced NSCLC With EGFR Mutation × Clear all
NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Henan Cancer Hospital

Phase 2 Unknown
200 enrolled
Thoracic

Advanced NSCLC With EGFR Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡